Ohio State Navbar

Our Team

Karl Haglund, MD, PhD


 

 

 

 

Assistant Professor, Radiation Oncology

 

 

 

 


Memberships

  • 2012-Present: ASTRO Abstract review committee, Sarcoma and Cutaneous Tumor section
  • 2012-Present: Radiation Therapy Oncology Group (RTOG), Translational Research Program, Immunomodulation Subcommittee
  • 2010-Present: CME/Maintenance of Certification Committee, Education Council, American Society for Radiology Oncology (ASTRO)

Manuscript Reviewer

  • 2010-Present: Rare Tumors 
  • 2010-Present: Practical Radiation Oncology 
  • 2013-Present: British Journal of Radiology

Research Activities

Laboratory:
  • 2009-2013: NIH, NCI, Intramural Laboratory Research: “Identification of Radiation Sensitizers in Chordoma from Promising Compounds Identified by High-throughput Screen” Collaborative effort with NCGC; NIH intramural funding.
  • 2010-2013: NIH, NCI, Intramural Laboratory Research: “Evaluation of Enhanced Anti-cancer Effects of Ionizing Radiation in the Presence of Compounds with Pro-Apoptotic Activities” Includes collaborative efforts with the University of Illinois at Urbana-Champaign and Agennix AG, Inc.; NIH intramural funding.
  • 2011-2013: NIH, NCI, Intramural Laboratory Research: “Synergy of Toll-like Receptor Agonists and Ionizing Radiation in the Generation of Local and Distant Anti-tumor Immune Responses.” NIH intramural funding.
  • 2012-2013: NIH, NCI, Intramural Laboratory Research: “Local and Distant Immune Responses against Lung Tumors after Ionizing Radiation and Inhibition of the Immunomodulators CTLA-4 and PD-1” NIH intramural funding.
Clinical:
  • 2011-2013: NIH, NCI, Clinical Protocol, Protocol Chair/Lead Associate Investigator: “Phase I trial of ECI301 in Combination with Radiation in Patients with Advanced or Metastatic Cancer”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy.”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols.”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “Collection of Peripheral Blood and/or Urine from Patients Undergoing Radiation Therapy.”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “The Natural History of Childhood Malignancies treated with Radiation Therapy.”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies.”
  • 2009-2013: NIH, NCI, Clinical Protocol, Associate Investigator: “A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation with Concurrent 5-Fluorouracil and Mitomyci-C for Stage I-III Carcinoma of the Anal Canal.”

Publications

  • Miller, Welliver, & Haglund. (Accepted 2014). Role of Modern Radiation in the Management of Extremity Sarcomas. Journal of Surgical Oncology
    Research Monographs:
  • Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G. (2013) Characterization and management of cardiac involvement of thymic epithelial tumors. J Thorac Oncol. 8(2):246-9.
  • Haglund, Raut, Nascimento, Wang, George, and Baldini (2012). Recurrence Patterns and Survival in Patients with Intermediate and High Grade Myxofibrosarcoma. Int J Radiat Oncol Biol Phys 82: 361-7.
  • Haglund and Viswanathan (2008). Computed tomography-based radiation therapy of ovarian remnants for symptomatic persistent endometriosis. Obstet Gynecol. 111: 579-83.
  • Haglund, Leiner, Kerksiek, Buonocore, Pamer, & Rose (2002). Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. Journal of Virology. 76: 7506-17.
  • Haglund, Leiner, Kerksiek, Buonocore, Pamer, & Rose (2002). High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. Journal of Virology. 76: 2730-8, Mar.
  • Davidson, Haglund, Stayner, Rakfeldt, Chinman, & Tebes (2001). "It was just realizing … that life isn't one big horror": a qualitative study of supported socialization. Psychiatric Rehabilitation Journal 24: 275-92.
  • Haglund, Forman, Krausslich, & Rose (2000). Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268: 112-21.
  • Anderson, Relucio, Haglund, Logan, Knowlton, Thompson, Steinmetz, Thompson & Greenough (1999). Effects of paired and unpaired eye-blink conditioning on Purkinje cell morphology. Learning & Memory 6: 128-37.
  • Lin, Sun, Heston, Gradoville, Shedd, Haglund, Rigsby, & Miller (1997). Identification, expression and immunogenicity of Kaposi's Sarcoma Associated Herpesvirus encoded small viral capsid antigen. Journal of Virology 71: 3069-76.
  • Rolls, Haglund, & Rose (1995). Expression of additional genes in a vector derived from a minimal RNA virus. Virology 218: 406-11.
  • Chen, Banerjea, Harmison, Haglund, & Schubert (1992). Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication -- potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Research 20, 4581-9.
  • Chen, Banerjea, Haglund, Harmison, & Schubert (1992). Inhibition of HIV-1 replication by novel multitarget ribozymes. Annals of the New York Academy of Sciences 660: 271-3.